Description

Indication & Scope

Letrozole Tablets (Femara®) is a high-selective non-steroidal aromatase inhibitor. It strongly inhibits aromatase activity, blocks peripheral estrogen synthesis in postmenopausal women, lowers systemic estrogen levels, and inhibits proliferation of estrogen-dependent breast cancer cells.

Mechanism
Selective aromatase inhibitor (AI)
Drug class
Prescription oral breast cancer endocrine therapeutic drug
Clinical use
Postmenopausal HR-positive early and advanced breast cancer

Specification

Generic Name	Letrozole Tablets
Brand Name	Femara®
Ingredient	Letrozole
Dosage Form	Film-coated tablets
Package	2.5mg*30 tablets/box
Conditions Treated	Adjuvant therapy for hormone receptor-positive early invasive breast cancer in postmenopausal women; Extended adjuvant treatment for early breast cancer after standard tamoxifen adjuvant therapy; First-line treatment for hormone receptor-positive advanced breast cancer in postmenopausal women
Taboos	Pregnant, breastfeeding and premenopausal women. Patients with hypersensitivity to letrozole or any excipients
Place of origin	Stein, Switzerland; Torre Annunziata, Italy
Priscription Type	Prescription Drug
Storage Conditions	Sealed, store below 30°C, protected from light
Manufacturer	Novartis Pharma Stein AG；Novartis Farma S.p.A.
Registration Authority	National Medical Products Administration (NMPA)
Approval number	HJ20140149
Approval Date	June 19, 2023
Shelf Life	60 months

How to use ?

Recommended Dose: Standard dose: 2.5 mg orally once daily, regardless of mealtimes.Standard dose: 2.5 mg orally once daily, regardless of mealtimes. Early breast cancer adjuvant treatment: Continuous medication for 5 years; eligible patients may receive extended endocrine therapy. Advanced breast cancer: Take uninterruptedly until disease progression or intolerable toxicity occurs.

Time: Take orally at a fixed time every day; no strict food limitation.

Interaction: Concomitant estrogen-containing preparations will counteract therapeutic effect, forbidden to use together. No obvious mutual influence with common chemotherapeutic agents. Strong CYP3A4 inducers may reduce blood concentration of letrozole, close observation is needed for combined use.

Side effects: Common adverse reactions: Hot flashes, joint and bone pain, fatigue, dizziness, headache, vaginal dryness, increased sweating. Less common: Nausea, diarrhea, alopecia, elevated liver enzymes, rash, edema. Major risks: Osteoporosis, elevated fracture risk, hyperlipidemia, cardiovascular adverse events.

Important Notice

This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support